

## Special Issue

# Alzheimer Disease: Controversies in Basic Science Research, Different Theories, and Reasons for Failed Trials

### Message from the Guest Editor

AD is a predominant, devastating, progressive chronic disease that begins as episodic memory lapses and progresses to changes in mood and personality and a decline of mental capacities. AD typically afflicts patients in their eighth or ninth decade of life, and its incidence rises steeply after 65 years of age. The global statistics on AD prevalence are ominous, and the 2018 cost of care is projected to be billions in the US alone. The emotional and spiritual costs to any family of a patient with dementia are immeasurable and irreplaceable. Such forbidding statistics has established AD as a profoundly disconcerting and very costly global health crisis. The aims of this Special Issue are to 1) highlight controversies or shortcomings of basic scientific research into AD so to help refocus research endeavours tackling AD; 2) collect reviews or original research articles that would potentially link the various theories on the aetiology and pathogenesis of AD and provide potentially unifying theories; and 3) collect analyses or discussions of the various reasons why so many clinical trials based on predominant theories of AD have failed so far.

### Guest Editor

Dr. Farid Rahimi

Division of Biomedical Science and Biochemistry, Research School of Biology, ANU College of Science, The Australian National University, Canberra, ACT 2600, Australia

### Deadline for manuscript submissions

closed (30 November 2020)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/20431](https://mdpi.com/si/20431)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).